Scinopharm Taiwan (TPE:1789) Cyclically Adjusted Book per Share: NT$15.62 (As of Dec. 2025)


TPE:1789 Scinopharm Taiwan Ltd TPE:1789
75 GF Score
Price NT$20.80
GF Value NT$27.20
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Cyclically Adjusted Book per Share?

Scinopharm Taiwan TPE:1789 -1.19% 75 Cyclically Adjusted Book per Share is NT$15.62 as of Dec. 2025. GuruFocus rates TPE:1789 with a GF Score™ of 75/100 and a GF Value™ of NT$27.20 (Modestly Undervalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Scinopharm Taiwan's adjusted book value per share for the three months ended in Dec. 2025 was NT$13.310. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$15.62 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Scinopharm Taiwan's average Cyclically Adjusted Book Growth Rate was 0.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Scinopharm Taiwan was 5.00% per year. The lowest was 1.20% per year. And the median was 2.90% per year.

As of today (2026-07-07), Scinopharm Taiwan's current stock price is NT$20.80. Scinopharm Taiwan's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$15.62. Scinopharm Taiwan's Cyclically Adjusted PB Ratio of today is 1.33.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Scinopharm Taiwan was 3.04. The lowest was 1.07. And the median was 1.70.


Scinopharm Taiwan  (TPE:1789) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Scinopharm Taiwan's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=20.80/15.62
=1.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Scinopharm Taiwan was 3.04. The lowest was 1.07. And the median was 1.70.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Scinopharm Taiwan Cyclically Adjusted Book per Share Related Terms


Scinopharm Taiwan Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Cyclically Adjusted Book per Share Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.25 15.08 15.33 15.52 15.62

Scinopharm Taiwan Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.52 15.66 15.71 15.75 15.62

TPE:1789 vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's Cyclically Adjusted PB Ratio falls into.


TPE:1789
75GF Score
Scinopharm Taiwan Ltd TPE:1789
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Scinopharm Taiwan's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=13.31/324.0540*324.0540
=13.310

Current CPI (Dec. 2025) = 324.0540.

Scinopharm Taiwan Quarterly Data

Book Value per Share CPI Adj_Book
201603 12.681 238.132 17.257
201606 12.593 241.018 16.932
201609 12.766 241.428 17.135
201612 12.934 241.432 17.360
201703 13.099 243.801 17.411
201706 12.939 244.955 17.117
201709 13.091 246.819 17.187
201712 13.174 246.524 17.317
201803 13.553 249.554 17.599
201806 13.317 251.989 17.125
201809 13.394 252.439 17.194
201812 13.328 251.233 17.191
201903 13.682 254.202 17.442
201906 13.179 256.143 16.673
201909 13.038 256.759 16.455
201912 12.975 256.974 16.362
202003 12.822 258.115 16.098
202006 13.129 257.797 16.503
202009 13.260 260.280 16.509
202012 13.316 260.474 16.566
202103 13.673 264.877 16.728
202106 13.134 271.696 15.665
202109 13.053 274.310 15.420
202112 13.293 278.802 15.451
202203 13.455 287.504 15.166
202206 13.130 296.311 14.359
202209 13.147 296.808 14.354
202212 13.216 296.797 14.430
202303 13.226 301.836 14.200
202306 12.870 305.109 13.669
202309 12.953 307.789 13.637
202312 13.107 306.746 13.847
202403 13.310 312.332 13.810
202406 13.117 314.175 13.529
202409 13.203 315.301 13.570
202412 13.311 315.605 13.667
202503 13.513 319.799 13.693
202506 12.986 322.561 13.046
202509 13.902 324.800 13.870
202512 13.310 324.054 13.310

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$15.62 mean?
Scinopharm Taiwan (TPE:1789) has a Cyclically Adjusted Book per Share of NT$15.62 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Cyclically Adjusted Book per Share too high?
Scinopharm Taiwan's current Cyclically Adjusted Book per Share is NT$15.62. Overall, Scinopharm Taiwan has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Scinopharm Taiwan's Cyclically Adjusted Book per Share of NT$15.62 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Cyclically Adjusted Book per Share is NT$15.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.20, compared to a current price of NT$20.80 — trading 23.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$15.62. Scinopharm Taiwan's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Cyclically Adjusted Book per Share is NT$15.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$20.80 is trading 23.5% below its estimated GF Value™ of NT$27.20. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Cyclically Adjusted Book per Share: NT$15.62
  • GF Value™: NT$27.20 vs. price of NT$20.80 (23.5% below fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
75GF Score

Get the complete analysis for TPE:1789

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.80
Price
NT$27.20
GF Value